Diffuse cutaneous systemic sclerosis
MONDO:0016356Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of Systemic Sclerosis (SSc) characterized by truncal and acral skin fibrosis with an early and significant incidence of diffuse involvement (interstitial lung disease, oliguric renal failure, diffuse gastrointestinal disease, and myocardial involvement).
Also known as: dSSc, diffuse cutaneous systemic scleroderma, progressive cutaneous systemic scleroderma, progressive cutaneous systemic sclerosis, DcSSc
66 clinical trials for this condition and its sub-types, 30 tagged with Diffuse cutaneous systemic sclerosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Umbilical cord stem cells tested for rare lung condition
Disease control CompletedThis study tested a single intravenous infusion of stem cells from donated umbilical cord tissue in one person with severe scleroderma that had caused lung scarring and high blood pressure in the lungs. The goal was to see if the treatment could improve lung function, exercise ab…
Phase 1/2 • Sponsor: Fundación Neumologica Colombiana • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stem cell transplant shows promise for scleroderma patients
Disease control CompletedThis study compared two treatment strategies for people with early, severe scleroderma: a stem cell transplant using their own cells versus standard immunosuppressive drugs. The trial enrolled 60 adults with diffuse cutaneous systemic sclerosis. The goal was to see which approach…
Phase 4 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for scleroderma: arthritis drug tofacitinib tested against skin thickening
Disease control CompletedThis study tested whether tofacitinib (a JAK inhibitor drug) works better than methotrexate (a standard treatment) at reducing skin thickening in people with a severe form of scleroderma called diffuse cutaneous systemic sclerosis. Thirty-four adults with early-stage disease took…
Phase 4 • Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for rare Skin-Hardening disease
Disease control CompletedThis study tested a new drug called MT-7117 (dersimelagon) in 76 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. Participants received either the drug or a placebo for 52 weeks. The main goal …
Phase 2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Cancer drug repurposed to fight rare skin disease in small safety trial
Symptom relief CompletedThis early-phase study tested whether a drug used for lymphoma, brentuximab vedotin, is safe for people with a severe form of scleroderma (diffuse cutaneous systemic sclerosis). The drug targets overactive immune cells that may drive the disease. Only 17 people took part, and the…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Blood cell counts may reveal clues about autoimmune diseases
Knowledge-focused CompletedThis study looked at specific cells in the blood of 40 women with either Sjögren's syndrome or systemic sclerosis. The goal was to see if counting these cells could help understand the diseases better. No treatment was given; it was purely an observational study to explore potent…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC